Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies
Identifieur interne : 000392 ( Main/Exploration ); précédent : 000391; suivant : 000393Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies
Auteurs : RBID : ISTEX:259_1991_Article_BF00175059.pdfEnglish descriptors
Abstract
To assess chemotherapeutically induced myocardial damage, myosin-specific antibody scans and ejection fraction measurements were performed in 32 patients with breast cancer and in 9 patients with other tumours. All patients had received chemotherapy including anthracyclines. The ejection fraction decreased by ≥ 10% in 14 of 41 (34%) patients after chemotherapy. Antimyosin uptake in the myocardium was observed in 38 of 41 (92%) patients after chemotherapy. Antimyosin uptake was quantified by means of a heart-to-lung ratio, revealing a correlation between the degree of antimyosin uptake in the myocardium and the cumulative dose of anthracycline. Patients with a decreased ejection fraction showed more intense antimyosin uptake, indicating more severe myocardial damage. A higher degree of antimyosin uptake was found in 17 breast cancer patients treated with doxorubicin compared with 15 patients treated with mitoxantrone. We conclude that antimyosin studies provide a sensitive, non-invasive method to monitor myocardial damage in patients treated with anthracyclines. Antimyosin uptake in the myocardium precedes ejection fraction deterioration. This technique may be helpful in the early identification of patients at risk of congestive heart failure during chemotherapy including anthracyclines.
DOI: 10.1007/BF00175059
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies</title><author><name>Ignasi Carrió</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author><author><name>Montserrat Estorch</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author><author><name>Lluis Berná</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author><author><name>Joseph R. Germá</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Oncology, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author><author><name>Carmen Alonso</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Oncology, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author><author><name>Belén Ojeda</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author><author><name>Luis de Andrés</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author><author><name>Antonio Lopez-Pousa</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Oncology, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author><author><name>Carlos Martinez-Duncker</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author><author><name>Gustavo Torres</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona</wicri:regionArea><wicri:noRegion>Barcelona</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1991_Article_BF00175059.pdf</idno><date when="1991">1991</date><idno type="doi">10.1007/BF00175059</idno><idno type="wicri:Area/Main/Corpus">000D16</idno><idno type="wicri:Area/Main/Curation">000D16</idno><idno type="wicri:Area/Main/Exploration">000392</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anthracycline toxicity</term><term>Cardiotoxicity</term><term>Myosin-specific monoclonal antibody studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">To assess chemotherapeutically induced myocardial damage, myosin-specific antibody scans and ejection fraction measurements were performed in 32 patients with breast cancer and in 9 patients with other tumours. All patients had received chemotherapy including anthracyclines. The ejection fraction decreased by ≥ 10% in 14 of 41 (34%) patients after chemotherapy. Antimyosin uptake in the myocardium was observed in 38 of 41 (92%) patients after chemotherapy. Antimyosin uptake was quantified by means of a heart-to-lung ratio, revealing a correlation between the degree of antimyosin uptake in the myocardium and the cumulative dose of anthracycline. Patients with a decreased ejection fraction showed more intense antimyosin uptake, indicating more severe myocardial damage. A higher degree of antimyosin uptake was found in 17 breast cancer patients treated with doxorubicin compared with 15 patients treated with mitoxantrone. We conclude that antimyosin studies provide a sensitive, non-invasive method to monitor myocardial damage in patients treated with anthracyclines. Antimyosin uptake in the myocardium precedes ejection fraction deterioration. This technique may be helpful in the early identification of patients at risk of congestive heart failure during chemotherapy including anthracyclines.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="e392040e214d5e4f8116e3522b69d0bc295170b0"><titleInfo lang="eng"><title>Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies</title></titleInfo><name type="personal"><namePart type="given">Ignasi</namePart><namePart type="family">Carrió</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><name type="personal"><namePart type="given">Montserrat</namePart><namePart type="family">Estorch</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><name type="personal"><namePart type="given">Lluis</namePart><namePart type="family">Berná</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><name type="personal"><namePart type="given">Joseph R.</namePart><namePart type="family">Germá</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Oncology, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><name type="personal"><namePart type="given">Carmen</namePart><namePart type="family">Alonso</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Oncology, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><name type="personal"><namePart type="given">Belén</namePart><namePart type="family">Ojeda</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><name type="personal"><namePart type="given">Luis</namePart><namePart type="family">de Andrés</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><name type="personal"><namePart type="given">Antonio</namePart><namePart type="family">Lopez-Pousa</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Oncology, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><name type="personal"><namePart type="given">Carlos</namePart><namePart type="family">Martinez-Duncker</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><name type="personal"><namePart type="given">Gustavo</namePart><namePart type="family">Torres</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Hospital de Sant Pau, Pare Claret 167, E-08025, Barcelona, Spain</affiliation></name><typeOfResource>text</typeOfResource><genre>Original Article</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateValid encoding="w3cdtf">2004-07-03</dateValid><copyrightDate encoding="w3cdtf">1991</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">To assess chemotherapeutically induced myocardial damage, myosin-specific antibody scans and ejection fraction measurements were performed in 32 patients with breast cancer and in 9 patients with other tumours. All patients had received chemotherapy including anthracyclines. The ejection fraction decreased by ≥ 10% in 14 of 41 (34%) patients after chemotherapy. Antimyosin uptake in the myocardium was observed in 38 of 41 (92%) patients after chemotherapy. Antimyosin uptake was quantified by means of a heart-to-lung ratio, revealing a correlation between the degree of antimyosin uptake in the myocardium and the cumulative dose of anthracycline. Patients with a decreased ejection fraction showed more intense antimyosin uptake, indicating more severe myocardial damage. A higher degree of antimyosin uptake was found in 17 breast cancer patients treated with doxorubicin compared with 15 patients treated with mitoxantrone. We conclude that antimyosin studies provide a sensitive, non-invasive method to monitor myocardial damage in patients treated with anthracyclines. Antimyosin uptake in the myocardium precedes ejection fraction deterioration. This technique may be helpful in the early identification of patients at risk of congestive heart failure during chemotherapy including anthracyclines.</abstract><subject lang="eng"><genre>Key words</genre><topic>Myosin-specific monoclonal antibody studies</topic><topic>Cardiotoxicity</topic><topic>Anthracycline toxicity</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1991</partNumber><partNumber>Volume: 18</partNumber><partNumber>Number: 10</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1991-10-01</dateIssued><copyrightDate encoding="w3cdtf">1991</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 16</identifier><recordInfo><recordOrigin>Springer-Verlag, 1991</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00175059</identifier><identifier type="matrixNumber">Art5</identifier><identifier type="local">BF00175059</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>806</start><end>812</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1991</recordOrigin><recordIdentifier>259_1991_Article_BF00175059.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000392 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000392 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1991_Article_BF00175059.pdf
|texte= Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies
}}
| This area was generated with Dilib version V0.5.81. |  |